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Abstract
Objectives. To examine secular trends in the progression of clinical and patient-reported outcomes in early RA.
Methods. A total of 2701 patients recruited to the Early Rheumatoid Arthritis Study or Early Rheumatoid Arthritis
Network with year of diagnosis from 1986 to 2011. The 5-year progression rates for patients diagnosed at different
points in time were modelled using mixed-effects regression; 1990, 2002 and 2010, were compared. Clinical
markers of disease included the 28-joint count DAS and the ESR. Patient-reported markers included the HAQ, vis-
ual analogue scale of pain and global health, and the Short-Form 36.
Results. Statistically significant improvements in both 28-joint count DAS and ESR were seen over the 5 years in
patients diagnosed with RA compared with those diagnosed earlier. By 5 years, 59% of patients with diagnosis in
2010 were estimated to reach low disease activity compared with 48% with diagnosis in 2002 and 32% with diag-
nosis in 1990. Whilst HAQ demonstrated statistically significant improvements, these improvements were small,
with similar proportions of patients achieving HAQ scores of 1.0 by 5 years with a diagnosis in 1990 compared
with 2010. Levels of the visual analogue scale and the Mental Component Scores of the Short-Form 36 indicated
similar, statistically non-significant levels over the 5 years, irrespective of year diagnosed.
Conclusion. This study demonstrates improvements in inflammatory markers over time in early RA, in line with
improved treatment strategies. These have not translated into similar improvements in patient-reported outcomes
relating to either physical or mental health.
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Introduction
The last 30 years have seen many changes in the pres-
entation of RA in the clinics, as well as how it is
managed therapeutically. Recent data from early RA
cohorts highlight how new RA patients are presenting
with increased levels of comorbidities and higher levels
of obesity [1], as well as increased levels of patient-
reported outcomes (PROs), such as pain and fatigue [2].
Alongside these changes in clinical presentation, a num-
ber of significant changes in the therapeutic manage-
ment of RA has also taken place. This includes the
switch to MTX as the anchor DMARD, the introduction
of biologic DMARDs (bDMARDs) and the adoption of a
treat-to-target approach [3, 4].
There is growing evidence that these therapeutic
changes have had positive effects on lowering inflam-
mation and halting the progression of structural joint
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damage [5–7]. Data from the Norfolk Arthritis
Register (NOAR) demonstrated that patients recruited
between 2000 and 2004 had significant improvements
in disease activity compared with those patients
recruited between 1990 and 1994 [8]. However, there
was little difference in functional disability, and there-
fore it is unclear whether these improvements in dis-
ease activity have translated into improvements in
key PROs, such as mental health, fatigue and pain
[9–12].
Studies have shown that psychological distress,
including depression and anxiety, is more prevalent in
patients living with RA [13–16], although its precise rela-
tionship with disease activity is not clear [17]. A recent
systematic review highlighted how health-related quality
of life (HRQoL) was reduced in RA populations, with
measures of physical function, bodily pain, fatigue and
mental well-being lower than that of the UK and US
general population [15]. Furthermore, health economic
evaluations have shown that those RA patients with
worse HRQoL outcomes are associated with higher
health care resource utilization [18]. Whilst few in num-
ber, longitudinal data from observational studies have
also sought to examine the long-term progression of
HRQoL outcomes for early RA patients. One study
showed that levels of psychological well-being and func-
tional disability remained relatively stable over a 10-year
period [19], whilst a study of a small cohort of early RA
patients in Sweden indicated greater improvements in
physical and mental health for both men and women
over a 6-year period [20].
Previous studies examining secular changes in
HRQoL outcomes have primarily focussed on functional
disability using the HAQ, as this is a common outcome
measure in arthritis. The current evidence base suggests
that whilst patients diagnosed and treated in earlier
cohorts demonstrate statistically significant differences
in HAQ, these changes relate to small absolute differen-
ces in the overall score [8, 11]. Despite reductions in
these HRQoL outcomes, these patients still exhibited
pronounced levels of pain and disability compared with
reference values [11].
To date, there has been no study utilizing longitudinal
analytical techniques to assess secular trends in long-
term trajectories of pain, functional disability and HRQoL
in early RA patients diagnosed over a 30-year time
frame. This study examines progression of disease ac-
tivity, functional disability and measures of HRQoL from
two early longitudinal RA cohorts, recruiting between
1986 and 2011. Longitudinal data for both cohorts
allows for the estimation of 60-month trajectories over
different time periods. It is hypothesized that 60-month
trajectories of disease activity and other objective
markers of inflammation have seen improvements in
more recent decades, but functional disability, pain and
HRQoL remain largely unchanged.
Methods
Patients
The data used for this study were collected from two
longitudinal inception cohorts: the Early Rheumatoid
Arthritis Study (ERAS) and the Early Rheumatoid Arthritis
Network (ERAN). ERAS recruited 1465 patients from
across the UK between 1986 and 2001, while ERAN
recruited 1236 patients from across the UK between
2002 and 2011. All patients had a confirmed diagnosis
of RA and were recruited within 2 or 3 years of symptom
onset, typically prior to conventional DMARD initiation.
Maximum follow-up for ERAS was 25 years (median
10 years) and for ERAN was 11 years (median 3 years).
Standard clinical, laboratory and radiographic data were
collected at baseline, 6 months and 12 months, and then
yearly thereafter.
Treatment
All patients were treated based on standard clinical
practice at the time [21]. For ERAS, this typically meant
DAMRD monotherapy, largely SSZ, with a gradual
switch to MTX over time [22]. For ERAN, SSZ and MTX
were used in equal proportions, with a shift to predom-
inately MTX towards the end. Median time to first
DMARD was 2 months for ERAS and 1 month for ERAN.
All patients in ERAS were DMARD naı̈ve, whereas in
ERAN a small proportion (13.5%) had commenced
DMARD therapy prior to baseline visit. Combination
DMARD therapies were reserved for more severe dis-
ease (around 25%) and, from 2002, <10% of patients
received bDMARDs by 3 years.
Measures
Disease activity score
For ERAS, the original three variable 44-joint DAS
(DAS44) was used to measure disease activity, com-
prised of the 44 swollen joint count, Ritchie Index for
tender joint count and ESR. For ERAN, the 4-variable
28-joint count DAS (DAS28) was used, comprised of the
revised 28 swollen joint count and tender joint count,
ESR and a Patient Global Assessment (PGA). For those
where ESR was missing, but a value of CRP was avail-
able, the DAS28-CRP version was used [23]. To enable
comparison of disease activity across the two cohorts,
the DAS44 in ERAS was converted to DAS28 using a re-
cently developed transformation formula that has been
validated in the ERAS cohort [24].
Functional disability
The UK version of the HAQ disability index was used to
collect data on patient’s functional disability [25].
Consisting of 20 items across eight domains of daily liv-
ing, it provides an overall disability score that ranges
from 0 to 3. Generally, a score of >1 indicates moderate
disability, whilst scores >2 indicate more severe
disability.
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Visual analogue scale
For patients recruited into ERAN, the PGA was
recorded, which is a sub-component of the DAS28 and
asks patients to rate their overall health on a visual ana-
logue scale (VAS) from 0 to 100. However, patients
recruited to ERAS did not record PGA (except in one
centre), but instead rated current pain levels using a 0–
100 VAS.
Whilst the focus of the item is specifically on pain for
ERAS, using a small subset of patients (n¼ 85) with
both the PGA and pain VAS, it was found that both
scores correlated highly (rICC¼0.9, P< 0.001), with
Bland and Altman plots indicating only a 0.39 mean dif-
ference (95% limits of agreement –23.57 to 22.80) be-
tween the scores. As such we decided it was
appropriate to compare changes in VAS over time
across both cohorts [26].
Short-Form 36
The Short-Form 36 (SF-36) was used to assess patients’
quality of life for ERAN patients only. Patients are
assessed on quality of life across eight domains;
Physical Function, Physical Role, Vitality, Mental Health,
Emotional Role, Bodily Pain, General Health and Social
Functioning. Two summary component scores are cal-
culated, the Physical Component Summary (PCS) and
Mental Component Summary (MCS). Scores are normal-
ized to the UK national average [27], whereby 50 indi-
cates the population average score and a difference of
10 units indicate 1 S.D. difference in the general popula-
tion (e.g. 16% of the general population score <40,
and 2% <30). The overall MCS and Mental Health sub-
domain will be used as measures of mental well-being,
whilst the Vitality sub-domain will be used as a measure
of fatigue.
Other clinical measures
Seropositivity was assessed using RF and for a subset
of patients recruited after 2000 anti-CCP was also
recorded. Patients who were positive on either RF or
anti-CCP were defined as seropositive, whilst those that
indicated negative to both were defined as seronegative.
ESR was recorded at each follow-up and used as an
objective marker of inflammation, along with CRP, which
was available in 46% of patients. Data on comorbidities
were recorded at each clinical visit and were coded
according to the 10th revision of the International
Classification of Diseases. These codes were used to
generate a weighted Charlson Comorbidity Index [28].
The score was modified to remove RA, as it was the
index condition for this study.
Statistical analysis
Descriptive analysis for all variables were explored for
both ERAS and ERAN to determine differences in demo-
graphic, clinical or laboratory data. Means and S.D., or
medians and interquartile range were used where appro-
priate depending on the distribution of the underlying
data. For categorical data, number of patients and
proportions of total cohort (excluding missing data) were
provided.
To examine the rate of progression of the DAS28,
HAQ, VAS, ESR and SF-36 over 5 years of follow-up,
mixed-effects linear regression models were used. The
analyses were restricted to 5 years since the rate of at-
trition was high beyond this point in the ERAN cohort.
Mixed-effects regression models with a random inter-
cept allows for the non-independence of data to be
accounted for, whereby each patient had repeated
observations over time. Preliminary analyses identified
each of the outcomes to have a non-linear progression
over the 5 years, indicating a greater change in the first
12 months (the initial treatment response), with a more
gradual change from months 12–60. To account for this,
months from baseline assessment was included in the
model as linear splines with knots at both 6 and
12 months. The models also controlled for important
confounding factors, including age at disease onset,
gender, seropositivity, baseline BMI, baseline Charlson
Comorbidity Index, and DMARD or steroid use prior to
baseline visit. The calendar year in which the patient
was diagnosed was entered as a main effect and with
an interaction term with month of follow-up, in order to
allow for different rates of change over time between
the different calendar periods. The model allowed for
estimated mean scores to be calculated at different
years of diagnosis, over the 60-month follow-up period.
These were used to display the trends over time graph-
ically for a number of selected dates; 1990, 2002 and
2010, along with corresponding 95% CIs. These dates
represented the early, middle and late end of both
cohorts combined.
Further analysis dichotomized each outcome to deter-
mine the proportion of patients achieving pre-specified
‘good’ outcomes by 60 months. DAS28 was based on
whether they achieved low disease activity (LDA)
(DAS28 3.2), ESR and PGA were based on achieving
10 units, reflecting Boolean remission critiera [29], HAQ
was based on achieving a score 1 [30], and SF-36
PCS and MCS were based on achieving scores
50 units, which reflects the UK population average.
The probability of achieving low scores over the
60 months was estimated using a mixed-effects logistic
regression analysis, following a similar modelling method
as the linear models described above. All analyses were
conducted using Stata (StataCorp. 2017. Stata Statistical
Software: Release 15. College Station, TX: StataCorp
LLC.) and significance was assumed at P< 0.05.
Ethics
The ERAS study received ethical approval from the
West Hertfordshire Local Research Ethics Committee
and subsequently from the Caldicott Guardian. The
ERAN study was approved by Trent Research Ethics
Committee (reference 01/4/047). All participants gave
signed, informed consent to participate in line with the
Declaration of Helsinki.
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Results
A summary of the demographic, and baseline clinical
and laboratory variables is shown in Table 1. Patients in
ERAN were older at onset and more likely to be female.
Mean baseline DAS28, VAS and HAQ levels were similar
across the two cohorts, whilst patients in ERAN had
lower mean levels of ESR and HAQ, along with a smaller
proportion of patients with seropositive RA.
In order to account for these differences in baseline
characteristics, all analyses controlled for age at disease
onset, gender, seropositivity status, baseline BMI and
baseline Charlson Comorbidity Index, along with steroid
or DMARD use prior to baseline visit.
Measures of disease activity and inflammation
Mixed-effects linear regression models were used to as-
sess the progression of the DAS28 and log-transformed
ESR over the first 5 years of the patient’s disease, with
estimated mean scores for patients diagnosed in 1990,
2002 and 2010. These are shown in Fig. 1. Comparisons
TABLE 1 Baseline demographic and clinical variables
Total N ¼ 2701 ERAS N 5 1465 ERAN N 5 1236
Years recruited
Range 1986–2011 1986–2001 2002–2011
Age at onset
N (missing) 2701 (0) 1465 (0) 1236 (0)
Mean (S.D.) 56.1 (14.43) 55.3 (14.57) 57 (14.22)
Median (IQR) 57 (46.0–67.0) 57 (45.0–66.0) 58 (47.0–68.0)
Range 0–93 17–93 0–89
Female
N (%) 1812 (67.09) 973 (66.42) 839 (67.88)
Missing (%) 0 (0) 0 (0) 0 (0)
Baseline BMI
N (Missing) 2392 (309) 1272 (193) 1120 (116)
Mean (S.D.) 26.5 (5.00) 25.6 (4.50) 27.6 (5.30)
Median (IQR) 25.9 (23.0–29.2) 25 (22.5–28.0) 26.8 (23.9–30.5)
Range 14–55 15–49 14–55
Baseline Charlson Comorbidity Index
N (missing) 2698 (3) 1465 (0) 1233 (3)
Mean (S.D.) 0.2 (0.61) 0.1 (0.38) 0.4 (0.80)
Median (IQR) 0 (0.0–0.0) 0 (0.0–0.0) 0 (0.0–0.0)
Range 0–7 0–3 0–7
Baseline DAS28
N (missing) 2588 (113) 1399 (66) 1189 (47)
Mean (S.D.) 4.8 (1.47) 5 (1.35) 4.6 (1.58)
Median (IQR) 4.9 (3.8–5.9) 5 (4.1–6.0) 4.7 (3.5–5.7)
Range 0–9 1–8 0–9
Baseline pain VAS
N (missing) 2642 (59) 1411 (54) 1231 (5)
Mean (S.D.) 43.8 (26.01) 44 (26.37) 43.5 (25.61)
Median (IQR) 45 (23.0–63.0) 45 (23.0–63.0) 45 (22.0–63.0)
Range 0–100 0–98 0–100
Baseline ESR
N (missing) 2511 (190) 1458 (7) 1053 (183)
Mean (S.D.) 37.2 (27.52) 42.2 (28.79) 30.2 (24.00)
Median (IQR) 30 (15.0–54.0) 37 (18.0–62.0) 24 (12.0–41.0)
Range 1–140 1–140 1–126
Baseline HAQ
N (missing) 2660 (41) 1460 (5) 1200 (36)
Mean (S.D.) 1.1 (0.77) 1.1 (0.77) 1.1 (0.76)
Median (IQR) 1 (0.5–1.6) 1 (0.5–1.8) 1 (0.5–1.6)
Range 0–3 0–3 0–3
Seropositive
N (%) 1569 (62.04) 914 (62.77) 655 (61.04)
Missing (%) 172 (6.37) 9 (0.61) 163 (13.19)
Baseline demographic and clinical variables for all patients and stratified by the separate ERAS and ERAN cohorts.
DAS28: 28 joint count DAS; ERAN: Early Rheumatoid Arthritis Network; ERAS: Early Rheumatoid Arthritis Study; IQR: inter-
quartile range; VAS: visual analogue scale.
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in the estimated mean scores at baseline and at month
60 between patients diagnosed in 2010 and 1990, and
between patients diagnosed in 2010 and 2002, are illus-
trated in Table 2. At baseline, there were statistically sig-
nificant differences between the three time periods, and
these were increased by month 60, where those diag-
nosed in 2010 had statistically significantly improved
DAS28 scores of 1.12 units (95% CI 0.90, 1.35) com-
pared with 1990 (P< 0.001) and of 0.45 units (95% CIs
0.36–0.54) compared with 2002 (P< 0.001).
This was also reflected in the mixed-effects logistic
regression model investigating the probability of
achieving LDA over the 60 months. Whilst it is esti-
mated that 31% of patients reached LDA by
60 months where they were diagnosed in 1990 [odds
ratio (OR) 0.31; 95% CI 0.28, 0.34], 50% reached LDA
in where they were diagnosed in 2002 (OR 0.50; 95%
CI 0.46, 0.53), and 63% were estimated to reach LDA if
they were diagnosed in 2010 (OR 0.63; 95% CI 0.57,
0.68).
The declines in DAS28 were in part due to reductions
in ESR levels, where patients diagnosed in 2010 had
significantly lower ESR at baseline and at month 60 rela-
tive to those diagnosed in 1990 (P< 0.001) and 2002
(P<0.001) (Fig. 1 and Table 2). This was also evident in
the logistic regression model, which estimated the prob-
ability of achieving a ESR 10, where 51% (OR 0.51;
95% CI 0.45, 0.58) of patients diagnosed in 2010 were
estimated to reach ESR levels 10, compared with 37%
(OR 0.37; 95% CI 0.34, 0.41) in 2002 and 20% (OR
0.20; 95% CI 0.18, 0.23) in 1990.
Measures of patient-reported outcomes
The results of the estimated mean scores for HAQ and
VAS from the mixed-effects linear models are given in
Fig. 2 and presented in Table 2. Whilst the models indi-
cated statistically significant improvements at baseline
and at month 60 between patients diagnosed in 2010
and 1990 (P<0.05) and between those diagnosed in
2010 and 2002 (P< 0.05) for both outcomes, these dif-
ferences were small. This is reflected in the logistic re-
gression models looking at the probability of achieving
HAQ scores 1.0 and VAS scores 10 units, where by
FIG. 1 Estimated mean scores of the DAS28 and ESR scores, along with the predicted probability of achieving LDA
and a ESR 10 over the first 60 months for patients diagnosed in 1990, 2002 and 2010
For the DAS28, black dotted lines indicate thresholds at 2.6 for remission, 3.2 for LDA and 5.1 for HDA. Shaded areas
represent the 95% CIs. Patients were diagnosed in: 1990 (circle markers solid line), 2002 (triangle marker solid line)
or 2010 (square marker dashed line). For the probability graphs, the red dotted line indicates the 50% probability
level. Models controlled for age at onset, gender, seropositivity status at baseline, baseline BMI, baseline Charlson
Comorbidity Index, and use of DMARDs and steroids at baseline assessment. DAS28: 28-joint count DAS; LDA: low
disease activity; HDA: high disease activity.
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FIG. 2 Estimated marginal means of the functional disability (HAQ) and VAS scores, along with the predicted probabil-
ity of achieving a HAQ 1 or a VAS of 10 units over the first 60 months for patients diagnosed in 1990, 2002 and
2010
Patients were diagnosed in: 1990 (circle markers solid line), 2002 (triangle marker solid line) or 2010 (square marker
dashed line). Shaded areas represent the 95% CIs. For the probability graphs, the red dotted line indicates the 50%
probability level. Models controlled for age at onset, gender, seropositivity status at baseline, baseline BMI, baseline
Charlson Comorbidity Index, and use of DMARDs and steroids at baseline assessment. VAS: visual analogue scale.
TABLE 2 Estimated differences of each outcome at baseline and 6-months between 2010, 2002 and 1990
DAS28 ESR
2010 vs 1990 2010 vs 2002 2010 vs 1990 2010 vs 2002
Delta 95% CI Delta 95% CI Delta 95% CI Delta 95% CI
Baseline 0.68*** 0.88, 0.47 0.27*** 0.35, 0.19 14.62*** 17.80, 11.43 4.90*** 5.76, 4.04
Month 60 1.12*** 1.35, 0.90 0.45*** 0.54, 0.36 10.49*** 12.30, 8.67 3.31*** 3.673, 2.89
HAQ VAS
2010 vs 1990 2010 vs 2002 2010 vs 1990 2010 vs 2002
Delta 95% CI Delta 95% CI Delta 95% CI Delta 95% CI
Baseline 0.15* 0.26, 0.05 0.06* 0.10, 0.02 1.20 4.570, 2.30 0.48 1.88, 0.92
Month 60 0.24** 0.36, 0.13 0.10** 0.14, 0.05 0.35 4.12, 3.42 0.14 1.65, 1.37
The estimated mean differences, along with their corresponding 95% CI, for the DAS28, ESR, HAQ and VAS at baseline
and at month 60 comparing patients diagnosed in 2010 with those diagnosed in 1990, and those diagnosed in 2010 with
those diagnosed in 2002. Models controlled for age at onset, gender, seropositivity status at baseline, baseline BMI, base-
line Charlson Comorbidity Index, and use of DMARDs and steroids at baseline assessment. *P<0.05, **P<0.01,
***P<0.001. DAS28: 28 joint count DAS; VAS: visual analogue scale.
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month 60 the probability for HAQ was similar across the
recruitment periods. Some 54% of patients indicated a
HAQ 1 at 60 months where they were diagnosed in
1990 (OR 0.54; 95% CI 0.51, 0.57), compared with 61%
of patients who were diagnosed in 2002 (OR 0.61; 95%
CI 0.58, 0.64) and 60% of patients diagnosed in 2010
(OR 0.65; 95% CI 0.60, 0.70) (Fig. 2). The VAS differed
from other PROs in that it indicated a statistically signifi-
cant improvement for those patients diagnosed in 1990
relative to 2002 and 2010 between the 6 and 48 months
of follow-up. However, like the other PROs, there was
no statistically significant difference at baseline, or by
month 60 (Table 2).
For those patients in the ERAN cohort where the SF-
36 was collected, mixed-effects linear models were
used to estimate both the PCS and MCS, as well as the
Physical Function, Bodily Pain, Vitality and Mental
Health sub-components. As the SF-36 data were only
available in ERAN, only 2002 and 2010 recruitment peri-
ods were modelled. The progression of these scores are
illustrated in Fig. 3, and relative differences between
2010 and 2002 are given in Table 3.
Relative to 2002, patients diagnosed in 2010 had sig-
nificantly better PCS at both baseline (P< 0.001) and
month-60 (P<0.05). This improvement was reflected by
similar improvements in both Physical Function and
Bodily Pain. However, by month 60, the magnitude of the
improvement had reduced. The improvement for patients
diagnosed in 2010 was reflected in a greater likelihood of
achieving a PCS 50 of 21% (OR 0.21; 95% CI 0.13,
0.28) by month 60, compared with those diagnosed in
2002 with just 5% (OR 0.05; 95% CI 0.02, 0.10).
In contrast, whilst patients diagnosed in 2010 experi-
enced significantly better MCS at baseline (P< 0.05) rela-
tive to those diagnosed in 2002, the magnitude of this
difference was much lower. As with the PCS, this differ-
ence diminished over time and by month 60 was statis-
tically non-significant. This was reflected in both the
Vitality and Mental Health sub-components. The likeli-
hood of achieving a MCS 50 units was similar in both
2010 (OR 0.42; 95% CI 0.29, 0.55) and 2002 (OR 0.58;
95% CI 0.49, 0.67).
FIG. 3 Estimated mean scores of the SF-36 PCS and MCS, along with the Physical Function, Bodily Pain, Vitality and
Mental Health sub-domain scores over the first 60 months for patients diagnosed in 2002 and 2010
The black dotted line represents a score of 50, the normalized population average. Patients were diagnosed in 2002
(circle marker) or 2010 (triangle marker). Shaded areas represent the 95% CIs. Models controlled for age at onset,
gender, seropositivity status at baseline, baseline BMI, baseline Charlson Comorbidity Index. and use of DMARDs
and steroids at baseline assessment. SF-36: Short Form-36; PCS: Physical Component Score; MCS: Mental
Component Score.
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Discussion
This study reports significant declines in disease activity
in RA over the last two decades, driven largely by
reductions in inflammatory markers. However, these
improvements in disease activity have not translated
into similar levels of improvements for mental health,
functional disability, or patient ratings of overall disease
activity, pain or vitality/fatigue, where levels have
remained relatively stable over the same period. These
findings are in keeping with other published work look-
ing at secular changes in PRO [9–12].
Compared with the data presented from the two
NOAR cohorts [8], the HAQ trajectories of the 1990 and
2002 cohort follow a similar pattern, albeit starting at a
slightly lower score. This is likely due to NOAR including
all inflammatory polyarthritic conditions, whereas ERAS
and ERAN were restricted to RA patients only. These
findings were also corroborated in a recent meta-
analysis using data from 29 early RA cohorts (including
ERAS and ERAN) of over 10 000 patients, which found
that levels of pain, fatigue, physical function and general
measures of mental health had not improved when com-
paring pre- and post-2002 cohorts of patients with early
RA. This is despite statistically and clinically meaningful
reductions in disease activity levels [31].
Differences in demographic and clinical outcomes at
presentation have been examined in this data in more
detail by the research team, which found increasing
prevalence of comorbid conditions, particularly cardio-
vascular and non-cardiac vascular morbidities, as well
as increases in BMI and age at disease onset [1].
However, despite decreased levels of ESR at presenta-
tion, there was little evidence of secular changes in dis-
ease activity levels or functional disability at diagnosis.
This analysis has developed these findings further to
show how these differences at presentation, in conjunc-
tion with changes in the treatment of RA, have affected
the long-term progression of important RA-related out-
comes. Whilst it is likely that adoption of more intensive
and aggressive treatment strategies are the primary driv-
ers for the decline in inflammatory markers of the dis-
ease [11, 32, 33], it is unclear whether the increases in
comorbidities and obesity are hampering equal improve-
ments in pain, fatigue and functional disability.
Using the SF-36 Vitality sub-domain, this study indi-
cated little change in levels of fatigue over time. Data
from the British Society for Rheumatology Biologics
Register for RA (BSRBR-RA) did indicate statistically
and clinically significant reductions in levels of fatigue
for those patients treated with anti-TNF-a [34]; how-
ever, despite these improvements, there were still a
substantial number of patients who achieved disease
remission that reported high levels of fatigue [35]. This
is suggestive of a heterogeneous RA population,
whereby a sub-group of patients are likely to experi-
ence increased levels of fatigue over the course of their
disease [36].
Previous studies have found little evidence of an asso-
ciation between inflammatory markers and fatigue [37],
and any associations with disease activity are likely to
be secondary to symptoms of pain and depression [38].
However, there is increasing evidence of a bi-directional
relationship between inflammatory markers, such as IL-6
and TNF-a, with depression [39]. The complex relation-
ship between depressive symptoms and inflammation,
along with the close associations between depression
with pain and fatigue, may in part explain why some
patients see improvements in these outcomes with more
effective anti-inflammatory therapies [39]. There is a
clear need for a conceptual framework that incorporates
these complex associations, in order that they be better
TABLE 3 Estimated differences of the Short-Form 36 at baseline and 6-months at 2010 and 2002
SF-36 PCS SF-36 PF SF-36 BP
2010 vs 2002 2010 vs 2002 2010 vs 2002
Delta 95% CI Delta 95% CI Delta 95% CI
Baseline 10.65*** 7.16, 14.14 7.13*** 3.17, 11.09 11.58*** 8.58, 14.57
Month 60 5.84* 1.36, 10.31 8.14** 3.17, 13.11 6.22** 2.26, 10.17
SF-36 MCS SF-36 VT SF-36 MH
2010 vs 2002 2010 vs 2002 2010 vs 2002
Delta 95% CI Delta 95% CI Delta 95% CI
Baseline 3.86* 0.56, 7.16 3.36* 0.18, 6.54 3.34* 0.25, 6.43
Month 60 1.96 6.27, 2.35 1.99 2.13, 6.11 2.10 1.93, 6.13
The estimated mean differences, along with their corresponding 95% CI, for the SF-36 PCS and MCS, along with the PF,
BP, VT and MH sub-domains at baseline and at month 60, comparing patients diagnosed in 2010 with those diagnosed in
2002. Models controlled for age at onset, gender, seropositivity status at baseline BMI, baseline Charlson Comorbidity
Index, and use of DMARDs and steroids at baseline assessment. *P<0.05, **P<0.01, ***P<0.001. SF-36: Short Form 36;
PCS: Physical Component Scale; MCS: Mental Component Scale; PF: Physical Function; BP: Bodily Pain; VT: Vitality; MH:
Mental Health.
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understood to inform identification and ultimately better
interventions [40].
Strengths and limitations
The use of prospective, observational cohort data allows
for the estimation of important outcomes in a true to life,
naturally treated, clinical setting. Unlike clinical trials,
where patients with high disease levels are typically
over-represented, the inclusive nature of the cohorts
allows for a wide spectrum of RA patients to be
included in the analysis. The emphasis on early RA also
allowed for the estimation of the progression of these
outcomes at treatment initiation.
However, prospective cohorts are prone to attrition
and missing data can hinder the statistical power of lon-
gitudinal analysis, particularly when examining group-
level differences. The presence of missing data was
largely accounted for through the use of mixed models,
which utilizes full-information maximum likelihood to es-
timate missing data using the predictions from observed
data in the models.
As ERAS is a historical cohort, it did not collect PGA
scores. In order to overcome this, pain scores measured
in ERAS using a 0–100 VAS were used. It could be
argued that both measures are measuring different con-
structs: PGA a more overall general health measure,
whereas pain VAS specifically targets RA-related pain.
Nevertheless, from a statistical point of view, these two
measures correlate highly, and demonstrate high levels
of agreement. As such, the pain score is likely to be a
suitable approximation of the ERAS patients’ PGA score
had they been collected routinely.
Conclusions
The role of improved therapeutic managements has
been instrumental in lowering inflammation and reducing
the inflammatory aspects of the disease over the last
30 years, the so-called objective markers. However,
there is a clear need to examine the subjective aspects
of the disease [41], which is driving the discordance be-
tween objective measures of inflammation, and the pa-
tient-reported measures [42]. Greater incorporation of
PRO in both clinical research and practice is vital, as
they measure important aspects of the disease not cur-
rently assessed in standard disease activity measures
[43]. These patient-reported factors have large implica-
tions on treatment decisions and call for multi-
disciplinary care to address all aspects of patients’
health [41, 44].
Future research should begin to focus on examining
possible sub-groups of patients that may progress dif-
ferently over time, as has already been evidenced with
HAQ [6, 45]. Early identification of patient sub-groups
who fair worse on pain, fatigue and mental health out-
comes, despite improvements in inflammation and gen-
eral markers of disease activity (so-called ‘persistent
symptoms’), would be useful in allocating resources and
identifying non-pharmacological therapies targeting
these specific aspects of the disease [44].
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